Aptorum Group Ltd - Ordinary Shares - Class A

NASDAQ:APM   10:21:27 AM EDT
3.18
+0.01 (+0.32%)
Products, Regulatory, Earnings Announcements

Aptorum Group Announces Positive Interim Phase I Clinical Trial Progress For ALS-4 Targeting Staphylococcus Aureus, And Positive Pre-INDProgress For SACT-1 Targeting Neuroblastoma

Published: 05/24/2021 12:30 GMT
Aptorum Group Ltd - Ordinary Shares - Class A (APM) - Aptorum Group Announces Positive Interim Phase I Clinical Trial Progress for Als-4 Targeting Staphylococcus Aureus and Positive Pre-ind Progress for Sact-1 Targeting Neuroblastoma.
Aptorum Group Ltd - Sact-1 on Track to Open an Ind to Commence Clinical Studies in Q3 2021.
Aptorum Group Ltd - Remaining Als-4 Phase I Study Will Continue to Progress.